New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
06:12 EDTRDS.A, XSRAY, XOM, GLNCY, EADSY, WMTOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Federal labor officials said their top priority is to decide whether to seek an injunction on behalf of Wal-Mart Stores (WMT) which filed a complaint last week to stop worker protests at its stores over the Thanksgiving holiday, the Wall Street Journal reports...The SEC is stepping up oversight of stock exchanges as they scramble to catch up to trading advantages that some say have developed for sophisticated clients at the expense of ordinary investors, the Wall Street Journal reports...REUTERS: Shareholders in commodity trader Glencore (GLNCY) voted overwhelmingly in favor of its $31B takeover of miner Xstrata (XSRAY), Reuters reports...Germany and France reached agreement under which each government would hold a 12% stake in EADS (EADSY) moving forward, according German newspaper Handelsblatt, Reuters reports...BLOOMBERG: Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and their partners in Kazakhstan’s Kashagan oil field face a delay of at least two years on a plan to boost output 20% percent, reducing the time they have to recoup costs in the $46B project that’s already running eight years late, sources say, Bloomberg reports...The 12 year rally in gold is set to continue next year as central bank stimulus spurs investors from John Paulson to George Soros to accumulate the highest combined bullion holdings ever, Bloomberg reports.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use